Scarica l'app Stockscreener
2.35
3.07%
0.07
Dopo l'orario di chiusura:
2.41
0.06
+2.55%
Precedente Chiudi:
$2.28
Aprire:
$2.54
Volume 24 ore:
1.34M
Relative Volume:
2.92
Capitalizzazione di mercato:
$66.63M
Reddito:
-
Utile/perdita netta:
$-28.85M
Rapporto P/E:
-1.6761
EPS:
-1.4021
Flusso di cassa netto:
$-25.62M
1 W Prestazione:
+16.92%
1M Prestazione:
-5.62%
6M Prestazione:
+3.98%
1 anno Prestazione:
+79.39%
Intervallo 1D:
$2.33
$2.77
Intervallo di 1 settimana:
$2.00
$2.77
Portata 52W:
$1.11
$5.50
Annovis Bio Inc Stock (ANVS) Company Profile
Nome
Annovis Bio Inc
Settore
Industria
Telefono
484-875-3192
Indirizzo
101 LINDENWOOD DRIVE, SUITE 225, MALVERN, PA
Compare ANVS vs VRTX, REGN, ARGX, ALNY, INSM
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ANVS
Annovis Bio Inc
|
2.35 | 64.65M | 0 | -28.85M | -25.62M | -1.4021 |
VRTX
Vertex Pharmaceuticals Inc
|
434.30 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
763.04 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
748.25 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
330.34 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
163.81 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Annovis Bio Inc Stock (ANVS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-02-10 | Downgrade | D. Boral Capital | Buy → Hold |
| 2024-10-25 | Aggiornamento | Maxim Group | Hold → Buy |
| 2023-12-29 | Iniziato | Canaccord Genuity | Buy |
| 2021-07-07 | Reiterato | Maxim Group | Buy |
Annovis Bio Inc Borsa (ANVS) Ultime notizie
Growth Value: Whats the analyst consensus on Annovis Bio IncMarket Movers & Verified Chart Pattern Signals - baoquankhu1.vn
Annovis Strengthens Patent Portfolio With Buntanetap, Stock Up - RTTNews
12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
ANVS.N Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Insider Buying: Annovis Bio (NYSE:ANVS) Director Acquires 713,800 Shares of Stock - MarketBeat
Annovis Bio Director Purchased Shares Worth Over $1.4M - TradingView
Director Michael Hoffman buys 713,800 Annovis Bio (ANVS) shares in open market - Stock Titan
Annovis Bio receives patent for buntanetap in brain infections By Investing.com - Investing.com Australia
[144] Annovis Bio, Inc. SEC Filing - Stock Titan
Annovis Bio, Inc. Secures Patent for Buntanetap in Prevention and Treatment of Neurological Injuries from Infectious Agents - Quiver Quantitative
Annovis Bio receives patent for buntanetap in brain infections - investing.com
Annovis Secures U.S. Patent for Buntanetap in the Prevention and Treatment of Neurological Injuries Caused by Brain Infections - ChartMill
ANVS Stock Price and Chart — NYSE:ANVS - TradingView
ANVS.N PE Ratio & Valuation, Is ANVS.N Overvalued - Intellectia AI
Annovis Publishes Historical Review of Buntanetap in The Scientist - Bitget
Bearish Setup: Will Annovis Bio Inc stock hit new highs in YEAR2026 Technicals & Growth-Oriented Investment Plans - baoquankhu1.vn
Annovis Bio Inc Stock: Phase 3 Progress in Alzheimer's and Parkinson's Therapies Drives Investor Foc - AD HOC NEWS
ANVS Technical Analysis | Trend, Signals & Chart Patterns | ANNOVIS BIO (NYSE:ANVS) - ChartMill
Annovis Partners With NeuroRPM to Add AI Monitoring in PD Study - MyChesCo
Annovis Bio, Inc. Files Form 8-K with NYSE Listing and Corporate Information for March 23, 2026 - Minichart
Annovis Bio CFO departs, CEO appointed as acting CFO By Investing.com - Investing.com Australia
Annovis Bio CFO departs, CEO appointed as acting CFO - Investing.com
Biopharmaceutical company Annovis Bio Inc announced that its CEO Maria Maccecchini will temporarily serve as CFO until the company finds a permanent replacement. - Bitget
Annovis Bio's Mark Guerin departs as CFO; Maria Maccecchini to serve as Acting CFO - TradingView
CFO departs Annovis Bio (ANVS) as CEO Maria Maccecchini takes acting finance role - Stock Titan
Annovis Bio, Inc. Announces Change of Chief Financial Officer - MarketScreener
Annovis Bio Secures Full Patent Protection for New Crystal Form of Alzheimer’s Drug Buntanetap - MSN
Annovis Reports 2025 Results, Advances Buntanetap Trials - MyChesCo
If You Invested $1,000 in Annovis Bio Inc (ANVS) - Stock Titan
ANVS SEC FilingsAnnovis Bio Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Market Rankings: Will Annovis Bio Inc stock recover after earnings2026 Chart Watch & High Conviction Buy Zone Picks - baoquankhu1.vn
Meme Stocks: Will Annovis Bio Inc benefit from rising consumer demand2026 Short Interest & Free Expert Verified Stock Movement Alerts - baoquankhu1.vn
Annovis Bio Publishes Data on New Crystal Form of Lead Alzheimer’s Drug - MSN
NeuroRPM Partners with Annovis for Parkinson's Disease Monitoring - Intellectia AI
Annovis Bio partners with NeuroRPM for Parkinson’s trial monitoring By Investing.com - Investing.com India
Annovis Bio partners with NeuroRPM for Parkinson’s trial monitoring - Investing.com
NeuroRPM to Deploy AI-Enabled Digital Biomarker Monitoring for Annovis Bio's Parkinson's Disease Clinical Trial - markets.businessinsider.com
Neurorpm To Deploy Ai-Enabled Digital Biomarker Monitoring For Annovis Bio's Parkinson's Disease Clinical Trial - TradingView
Annovis Partners with NeuroRPM to Deploy AI-Powered Digital Biomarker Technology in Parkinson's Disease Study - The Manila Times
Annovis Stock Rises After Company Confirms Meeting With Regulators To Discuss Drug In Treating Parkinson's Disease Dementia - MSN
Annovis Bio CEO to Present at H.C. Wainwright Global Investment Conference - MSN
Shorts Report: Is Annovis Bio Inc stock forming a triangle pattern2026 Gainers & Real-Time Volume Analysis Alerts - baoquankhu1.vn
Chart Watch: Should you avoid Annovis Bio Inc stock right now2026 Performance Recap & Low Risk High Win Rate Picks - baoquankhu1.vn
ANVS Technical Analysis & Stock Price Forecast - Intellectia AI
Annovis Bio Reports Promising Biomarker Results Showing Anti-Inflammatory, Neuroprotective Effects of Buntanetap in Alzheimer’s Patients - MSN
Phase 3 trial push deepens 2025 loss at Annovis Bio (NYSE: ANVS) - Stock Titan
Annovis Bio shares are trading higher. The company reported Q4 financial results.Annovis Bio (NYSE:ANVS) - Benzinga
Annovis Provides Corporate Updates and Reports Fiscal Year 2025 Financial Results - Bitget
Annovis Bio, Inc. Announces Business Updates and Financial Results for Fiscal Year 2025, Highlighting Pivotal Advances in Buntanetap Development for Neurodegenerative Diseases - Quiver Quantitative
Annovis Bio Q4 EPS $(0.39) Misses $(0.34) EstimateAnnovis Bio (NYSE:ANVS) - Benzinga
Annovis Bio (ANVS) Stock Analysis Report | Financials & Insights - Benzinga Japan
Annovis Bio Inc Azioni (ANVS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.87%
0.11%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):